查看完整行情页>>

|

货币单位:美元(USD)

Applied Genetic Technologies Corp. (agtc)

实时(?):
盘后(?):
读取中...
  • -- (--%)
开盘价:-- 最高价:-- 最低价:-- 52周最高价:-- 52周最低价:--
成交量:-- 平均成交量:-- 市值:-- 市盈率:-- 预期市盈率:--
每股收益:-- 贝塔系数:-- 股息:-- 收益率:-- 总股本:--
Ivana Magovcevic-Liebisch Ivana Magovcevic-Liebisch is President, Chief Executive Officer & Director at Vigil Neuroscience, Inc. She is also on the board of Aeglea Biotherapeutics, Inc., Suffolk University, Applied Genetic Technologies Corp. and AbSci Corp. In her past career she occupied the position of Chief Strategy & Development Officer, Executive VP at Axcella Health, Inc., Chief Business Officer & Executive Vice President at Ipsen SA, Senior VP & Head-Global Business Development at Teva Pharmaceutical Industries Ltd., Chief Operating Officer & Executive Vice President of Dyax Corp. and Director-Intellectual Property & Patent Counsel at Transkaryotic Therapies, Inc. She received a doctorate from Harvard University, a graduate degree from Suffolk University Law School and an undergraduate degree from Wheaton College (Illinois).
Ed M. Hurwitz Ed M. Hurwitz founded Precision BioVentures LLC and Viewpoint Therapeutics, Inc. He holds the position of Chairman of Viewpoint Therapeutics, Inc., Chairman of Biointervene, Inc., Chief Financial Officer of Turmeric Acquisition Corp. and Managing Director at MPM Capital LLC. Mr. Hurwitz is also Manager for Alta Embarcadero Biopharma Partners III LLC and on the board of 7 other companies. Mr. Hurwitz previously held the position of Managing Director at Precision BioVentures LLC, Director at Alta Partners Management Corp. and Chief Financial Officer & Senior Vice President for Affymetrix, Inc. Ed M. Hurwitz received an undergraduate degree from Cornell University, an MBA from Haas School of Business and a graduate degree from Berkeley Law University of California.
Anne M. VanLent Anne M. VanLent founded AMV Advisors and Technology Compass Group LLC. Presently, she occupies the position of President at AMV Advisors. She is also on the board of International AIDS Vaccine Initiative, Inc., Applied Genetic Technologies Corp., Trevi Therapeutics, Inc. and Vaxart, Inc. In the past Anne M. VanLent was Principal at Technology Compass Group LLC, Chief Financial Officer & Executive Vice President for Barrier Therapeutics, Inc., Chief Financial Officer & Senior Vice President of The Liposome Co., Inc. and Executive Vice President-Portfolio Management at Sarnoff Corp. Ms. VanLent received an undergraduate degree from Mount Holyoke College.
Arnold Lewis Oronsky Presently, Arnold Lewis Oronsky is Chairman at EpicentRx, Inc. and Managing Director at InterWest Partners, LLC. He is also Managing Partner at Interwest Venture Management Co. and on the board of 10 other companies. Dr. Oronsky previously was Chairman at Dynavax Technologies Corp., Vice President-Discovery Research at Lederle Laboratories, Head-Inflammation, Allergy & Immunology Research at Ciba-Geigy Corp., Head-Inflammation, Allergy & Immunology at Ciba-Geigy Pharmaceuticals and Vice President-Discovery Research at Wyeth Holdings LLC. He received a doctorate from Columbia University and an undergraduate degree from New York University.
Scott E. Koenig Scott E. Koenig founded MacroGenics, Inc. Currently, he occupies the position of Chairman at Applied Genetic Technologies Corp. and President, Chief Executive Officer & Director at MacroGenics, Inc. He is also on the board of Biotechnology Innovation Organization, GlycoMimetics, Inc. and The International Biomedical Research Alliance and Member of Cornell University Council. In the past Scott E. Koenig occupied the position of Senior Vice President-Research at Medimmune, Inc., Principal at National Institute of Allergy & Infectious Diseases, Chairman for Children's Research Institute, Inc., Principal at National Institutes of Health and Trustee-Advisory Board at Cornell University. He received a doctorate and an undergraduate degree from Cornell University and a doctorate from The University of Texas Health Science Center at Houston.
Susan B. Washer Currently, Susan B. Washer occupies the position of President, Chief Executive Officer & Director at Applied Genetic Technologies Corp. She is also on the board of 8 other companies. Ms. Washer previously was President & Chief Executive Officer for Scenic Productions, Inc., Principal at Eli Lilly & Co. and Principal at Abbott Laboratories (Pakistan) Ltd. She received an undergraduate degree from Michigan State University, an MBA from Warrington College of Business Administration and an MBA from the University of Florida.
James Rosen Mr. James Rosen is an Independent Director at Applied Genetic Technologies Corp., a Principal at Intersouth Partners, a Chief Executive Officer at Artizan Biosciences, Inc., a Director-Public Health Foundation at Unc Gillings School of Global Public Health and a Partner at Intersouth Associates VI LLC. He is on the Board of Directors at Applied Genetic Technologies Corp. Mr. Rosen was previously employed as an Equity Research Analyst by Brean Murray & Co., a Principal by Duke University Medical Center, and a Principal by The Robert Wood Johnson Foundation. He also served on the board at Viamet Pharmaceuticals Corp., Advanced Animal Diagnostics, Inc., Viamet Pharmaceuticals, Inc., 480 Biomedical, Inc. and Public Health Foundation. He received his undergraduate degree from Duke University, a graduate degree from Unc Gillings School of Global Public Health and an MBA from Kenan-Flagler Business School.
William E. Aliski William E. Aliski is on the board of Ultragenyx Pharmaceutical, Inc., Applied Genetic Technologies Corp. and X4 Pharmaceuticals, Inc. In his past career he held the position of General Manager-BioMarin Europe at BioMarin Pharmaceutical, Inc., Vice President-Patient & Product Services at Genzyme Corp., Chief Commercial Officer & Senior Vice President at FoldRx Pharmaceuticals, Inc. and Vice President-Commercial Operations at Transkaryotic Therapies, Inc. Mr. Aliski received an undergraduate degree and a graduate degree from Boston College and a graduate degree from Harvard Kennedy School of Government.
William A. Sullivan Founder of District Cider Co., Inc., William A. Sullivan currently holds the position of President of District Cider Co., Inc., Chief Financial Officer of Applied Genetic Technologies Corp. and Associate of TA Associates Management LP. In the past he occupied the position of Treasurer, Chief Financial & Accounting Officer at Merrimack Pharmaceuticals, Inc. and Controller at Vette Corp. William A. Sullivan received an undergraduate degree from Williams College and a graduate degree and an MBA from Northeastern University.
Matthew Feinsod Founder of Imagen Biotech, Inc., Matthew Feinsod presently occupies the position of Chief Medical Officer at Imagen Biotech, Inc. and EVP-Global Strategy & Development at Applied Genetic Technologies Corp. He is also on the board of World Eye Mission. Dr. Feinsod previously held the position of Medical Officer at US Food & Drug Administration, Senior VP-Strategy & Product Development at Eyetech Pharmaceuticals, Inc. and Director-University Hospitals Institutional at George Washington University. Matthew Feinsod received a doctorate from George Washington University and an undergraduate degree from The Wharton School of the University of Pennsylvania.
Mark S. Shearman Currently, Mark S. Shearman occupies the position of Chief Scientific Officer & Vice President at Applied Genetic Technologies Corp. In the past Dr. Shearman held the position of Senior VP-Research & Early Development at EMD Serono, Inc. He received an undergraduate degree from the University of Bristol and a doctorate from The University of Nottingham.
Ellery Mangas Mr. Ellery Mangas is Senior Director-Regulatory Affairs at Applied Genetic Technologies Corp.
Karen M. Carroll Karen M. Carroll is Vice President-Clinical Development Operations at Applied Genetic Technologies Corp.
Brian Krex Brian Krex holds the position of General Counsel at Applied Genetic Technologies Corp. In his past career Mr. Krex was Associate at Moses & Singer LLP, Chief Counsel & Assistant General Counsel at Pfizer Inc. and VP, Global Head-Commercial & Regulatory Law at Alexion Pharmaceuticals, Inc. Mr. Krex received an undergraduate degree from Bard College and a graduate degree from Seton Hall University School of Law.
Nnenna Ihekoromadu Currently, Nnenna Ihekoromadu holds the position of VP-Clinical Research & Medical Affairs at Applied Genetic Technologies Corp.